In an effort to reign in the hype surrounding stem cell research that has led to a proliferation of unapproved and potentially dangerous stem cell therapies, the International Society for Stem Cell Research (ISSCR) recently released updated guidelines outlining conduct for stem cell researchers that, for the first time, included communications activities.
NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (NASDAQ: STEM) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study’s Interim Analysis Data Monitoring Committee (the “IA-DMC”).
LOUISVILLE and NEW YORK, May 25, 2016 /PRNewswire-USNewswire/ — The National Stem Cell Foundation (NSCF) and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) have announced a partnership to fund development of a cutting-edge therapy to replace the dopamine neurons that degenerate in Parkinson’s disease, the second most common brain disease after Alzheimer’s.
Data Included in Newly Submitted Patent Application for AST-OPC1- FREMONT, Calif. May 24, 2016 – Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced new positive long-term follow-up results from its Phase 1 clinical trial assessing the safety of AST-OPC1 (oligodendrocyte progenitor cells) in patients with spinal cord injury.
Click here for the full Guidelines document Listen to an audio recording of the 12 May news conference Washington, D.C.; 12 May 2016 – The International Society for Stem Cell Research (ISSCR), the world’s largest professional organization of stem cell scientists, today released newly updated guidelines for stem cell research and the development of new clinical therapies.
HOME › ABOUT THE FOUNDATION › Press Releases › March 24,2016 Papers filed with California Attorney General’s Office for dissolution of PAN as independent 501(c)3 Key PAN staff will join Foundation as part of MJFF’s new public policy team Consolidation aims to streamline mission to advance Parkinson’s policy priorities and better treatments for 1 million U.S.
Recent news of an impending clinical cell transplantation trial in Parkinson’s disease using parthenogenetic stem cells as a source of donor tissue have raised hopes in the patient community and sparked discussion in the research community. Based on